title: Effect of bevantolol and propranolol on serum lipids in patients with essential hypertension.
abstract: In patients with essential hypertension, the beta-blockers bevantolol or propranolol were administered once or twice a day for twelve weeks to evaluate the effects on blood pressure, and lipid metabolism. Both systolic and diastolic blood pressure decreased significantly in response to both bevantolol and propranolol. The pulse-rate also decreased significantly in both groups. Total cholesterol did not change significantly in both groups. Triglycerides increased significantly in the bevantolol group. HDL cholesterol decreased significantly in the propranolol group. The LDL cholesterol/HDL cholesterol ratio increased significantly in the propranolol group, while no significant increase was observed in the bevantolol group. The apolipoprotein B/A ratio was elevated in the propranolol group. No serious side-effects were noted during the study in both groups. These results indicate that bevantolol is an effective antihypertensive drug with fewer unfavorable effects on lipid metabolism than propranolol.
authors.affiliation: 2nd Department of Internal Medicine, Fukuoka University, School of Medicine, Japan.
authors.forename: J
authors.initials: J
authors.lastname: Sasaki
authors.forename: G
authors.initials: G
authors.lastname: Kajiyama
authors.forename: R
authors.initials: R
authors.lastname: Kusukawa
authors.forename: H
authors.initials: H
authors.lastname: Mori
authors.forename: S
authors.initials: S
authors.lastname: Koga
authors.forename: R
authors.initials: R
authors.lastname: Takagi
authors.forename: N
authors.initials: N
authors.lastname: Tanaka
authors.forename: N
authors.initials: N
authors.lastname: Ogawa
authors.forename: K
authors.initials: K
authors.lastname: Arakawa
mesh_terms: D000319:Adrenergic beta-Antagonists / Q000494:pharmacology* / Q000627:therapeutic use; D000328:Adult; D000368:Aged; D001053:Apolipoproteins / Q000097:blood / Q000187:drug effects; D001794:Blood Pressure / Q000187:drug effects; D005230:Fatty Acids, Nonesterified / Q000097:blood; D005260:Female; D006801:Humans; D006973:Hypertension / Q000097:blood / Q000188:drug therapy* / Q000503:physiopathology; D008055:Lipids / Q000097:blood*; D008074:Lipoproteins / Q000097:blood / Q000187:drug effects; D008297:Male; D008875:Middle Aged; D011412:Propanolamines / Q000494:pharmacology* / Q000627:therapeutic use; D011433:Propranolol / Q000494:pharmacology*; D014280:Triglycerides / Q000097:blood
chemical_list: D000319:Adrenergic beta-Antagonists; D001053:Apolipoproteins; D005230:Fatty Acids, Nonesterified; D008055:Lipids; D008074:Lipoproteins; D011412:Propanolamines; D014280:Triglycerides; C021148:bevantolol; D011433:Propranolol